Skip to main content
. 2020 Sep 24;24:574. doi: 10.1186/s13054-020-03293-8

Table 1.

Demographics and clinical characteristics at admission and treatment of patients

Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (Y) 52 78 63 51 71 55
Sex Male Male Male Female Male Male
BMI 31 35 26 54 28 37
Comorbidities Obesity Obesity, coronary artery disease, arterial hypertension Bronchial asthma Obesity, arterial hypertension, rheumatoid arthritis Type 2 diabetes mellitus Obesity, arterial hypertension
Invasive ventilation Yes Yes Yes Yes Yes Yes
Severity of ARDS at admission Moderate Moderate Moderate Moderate Severe Moderate
Anti-infective therapy Imipeneme Imipeneme Imipeneme, voriconazol Piperacillin/tazobactam, ciprofloxa-cin, meropenem, vancomycin, anidulafun-gin Merope-neme, co-trimoxazol Ampicillin/sulbactam, cephazolin, caspofungin
Days on ICU prior to FX06 treatment 0 3 4 10 15 2
SAPS II Score 57 75 43 68 63 59
PaO2/FiO2 ratio at admission 186 141 131 154 85 122
Daily dose of FX06 500 mg 600 mg 400 mg 400 mg 400 mg 400 mg
Duration of FX06 treatment (days) 7 7 4 3 4 4
vv-ECMO therapy Yes No Yes Yes Yes Yes
Outcome Rehabilitation care (after 35 days) Death Rehabilitation care (after 70 days) Death Rehabilitation care (after 48 days) Rehabilitation care (after 44 days)
Laboratory results at admission Reference range
 White blood cell count (cells per 106/L) 14.02 15.56 6.26 7.9 14.2 11.2 3.92–9.81
 Lymphocyte (cells per 106/L) 1.12 1.24 0.71 0.92 1.44 1.32 1.05–3.24
 Platelets 320 147 171 161 272 255 146–328
 LDH U/L 378 1277 417 611 516 609 < 248
 Creatinine mg/dL 0.72 2.34 0.43 0.50 0.82 0.88 0.7–1.2
 C-reactive protein (mg/dL) 20.13 18.08 8.00 15.64 18.09 24.85 < 0.5
 Ferritin ng/mL 883 5505 3708 1114 4079 3503 (day 3) 18–360
 Procalcitonin ng/mL 0.15 0.30 0.78 0.09 1.32 2.44 < 0.5
 Lactate mg/dL 9.0 14 9.0 8.1 12.6 13.5 4.5–14.5
 IL-6 pg/mL 92.3 25.4 250 2647.0 440.9 360.1 < 7
 D-dimer ng/mL 629 130,100 1056 450 2850 3750 < 500
 aPTT (s) 28 30 29 48.6 44.0 37.8 25–37
 vWF AG (%) 283 446 311 n/a > 150 > 150 60–150

Demographics and clinical characteristics at admission and treatment of patients

Y years, BMI body mass index, ARDS acute respiratory distress syndrome, SAPS simplified acute physiology score, LDH lactate dehydrogenase, U units, aPTT activated partial Thromboplastin time, VWF AG von Willebrand factor antigen, SAPS II Simplified Acute Physiology Score, PaO2 partial pressure arterial oxygen, FiO2 fraction of inspired oxygen, vv veno-venous, ECMO extracorporeal membrane oxygenation